The First Drug With A $1 Million Price Tag May Already Be On The Market

That red line is Naglazyme, which treats Maroteaux–Lamy syndrome, a disease that causes dwarfism, heart problems, and nerve problems. The treatment, sold by BioMarin, costs about $350,000 for the average patient. For kids under five, as the chart shows, the cost would actually be well less than that. But what happens as those children get older?


you can see, at current pricing, the cost of Naglazyme will pass $1 million as patients hit their teen years, and reach $1.3 million as they approach their 40s. Of course, it’s not certain that this will happen; one could imagine that the price may need to drop over the coming decades. But this shows how very expensive these drugs are.
 
Update: to be clear, only some patients will pay this per patient per year cost; the average cost could still be lower than that of, say, Soliris, because some of the patients on Naglazyme will be kids.
Más